jpad journal
IF 2023 : 8.5

AND option

OR option

CTAD 2025

The 18th Clinical Trials on Alzheimer’s Disease conference (CTAD), will be held in San Diego (USA) on December 1-4, 2025

The Clinical Trials on Alzheimer’s Disease (CTAD) Conference, established in 2008, has become a cornerstone event in Alzheimer’s disease (AD) clinical research. Designed by and for AD researchers, CTAD’s mission is to create a platform that prioritizes substantive, clinical research-focused dialogue and collaboration. By fostering an intimate and collegial environment, CTAD has gained a reputation for facilitating impactful international collaborations and advancing the global AD research agenda.

The upcoming 18th annual CTAD conference (CTAD25) will take place in San Diego, USA, from December 1-4, 2025. CTAD25 is poised to build on the momentum of previous years, reflecting the rapid advancements in Alzheimer’s disease diagnostics and therapeutics that make this field one of the most dynamic in medical research today.

At the recently concluded CTAD24 in Madrid, Spain, over 2,500 international leaders convened to discuss groundbreaking developments in AD clinical research. Highlights from 2024 included:

  • The one-year experience of recently marketed anti-amyloid treatments.
  • Integration of blood biomarkers into clinical practice and trials.
  • Promising results from Phase 1 and Phase 2 AD clinical trials.

CTAD24 also featured thought-provoking roundtables and symposia that explored the latest advancements in AD research. Renowned clinicians and leaders from academia, research centers, patient coalitions, and pharmaceutical companies engaged in dynamic discussions on diverse topics, from disease-modifying agents to gene therapy, vaccines, and multimodal interventions. CTAD continues to expand its focus beyond amyloid-clearing treatments, embracing innovative approaches to address the complexity of Alzheimer’s disease.

The CTAD scientific program is underpinned by a rigorous peer-review abstract selection process, ensuring the presentation of high-quality research that drives the field forward.

CTAD is also closely associated with the Journal of Prevention of Alzheimer’s Disease (JPAD), the conference’s official journal. JPAD publishes peer-reviewed articles, including reviews, original research, and short reports, on topics critical to Alzheimer’s prevention. These include neuroscience, biomarkers, imaging, epidemiology, public health, geroscience, physical and cognitive exercise, nutrition, risk and protective factors, drug development, trial design, and health economic outcomes. With a 2023 Impact Factor of 8.5, JPAD is a leading publication in the field..

CTAD and JPAD remain committed to advancing Alzheimer’s disease research and prevention, fostering collaboration among global leaders, and supporting the dissemination of innovative findings to improve patient outcomes.and Scientific Translations & Editing

Ph: +33 6 10 25 38 96

email: benedicteclement2507@gmail.com

Comité d'organisation

logo CTAD Jpeg

For more information please visit our website www.ctad-alzheimer.com or contact the CTAD 2025 secretariat at ctad@ant-congres.com

CTAD 2025 Scientific Committee

President of the CTAD25 Scientific Committee

  • Susan ABUSHAKRA (San Francisco, USA)
  • Paul AISEN (San Diego, USA)*
  • Rebecca E. AMARIGLIO (Boston, USA)
  • Sandrine ANDRIEU (Toulouse, France)*
  • Davide ANGIONI (Toulouse, France)
  • Laura BAKER (Winston-Salem, USA)
  • Randall J. BATEMAN (St. Louis, USA)
  • Karim BENNYS (Montpellier, France)
  • Kaj BLENNOW (Molndal, Sweden)
  • Merce BOADA (Barcelona, Spain)
  • Marc CANTILLON (Livingston, USA)
  • Maria CARRILLO (Chicago, USA)
  • Suzanne CRAFT (Winston-Salem, USA)
  • Suzanne CRAFT (Winston-Salem, USA)
  • Lucia CRIVELLI (Buenos Aires, Brazil)
  • Steven DEKOSKY (Gainesville, USA)
  • Michael C DONOHUE (San Diego, USA)
  • Rachelle DOODY (Houston, USA)
  • Bruno DUBOIS (Paris, France)
  • Howard FELDMAN (San Diego, USA)
  • Howard FILLIT (New York, USA)
  • Nick FOX (London, UK)
  • Kristian Steen FREDERIKSEN (Copenhagen, Denmark)
  • Giovanni B. FRISONI (Brescia, Italy)
  • Serge GAUTHIER (Montreal, Canada)
  • Joshua GRILL (Los Angeles, USA)
  • Michael GRUNDMANN (San Diego, USA)
  • Harald HAMPEL (Nutley, USA)
  • Oskar HANSSON (Lund, Sweden)
  • Tobias HARTMANN (Homburg, Germany)
  • Takeshi IWATSUBO (Tokyo, Japan)
  • Frank JESSEN (Cologne, Germany)
  • Ara KHACHATURIAN (Washington DC, USA)
  • Zaven KHACHATURIAN (Washington DC, USA)
  • Miia KIVIPELTO (Stockholm, Sweden)
  • Yan LI (St. Louis, USA)
  • Jorge J. LLIBRE GUERRA (St. Louis, USA)
  • Constantine G. LYKETSOS (Baltimore, USA)
  • Gad A. MARSHALL (Boston, USA)
  • Lefkos T. MIDDLETON (London, UK)*
  • José Luis MOLINUEVO (Valby, Denmark)
  • Claire PAQUET (Paris, France)
  • Robert PERNECZKY (Munich, Germany)
  • Ronald PETERSEN (Minnesota, USA)
  • Michael S. RAFII (San Diego, USA)
  • Rema RAMAN (San Diego, USA)
  • Craig W. RITCHIE (Edinburgh, UK)
  • Robert RISSMAN (San Diego, USA)
  • Marwan SABBAGH (Phoenix,  USA)
  • Stephen SALLOWAY (Providence, USA)
  • Pascual SANCHEZ-JUAN (Madrid, Spain)
  • Nikolaos SCARMEAS (New York, USA)
  • Rachel SCHINDLER (New York, USA)
  • Philip SCHELTENS (Amsterdam, NL)
  • Lon SCHNEIDER (Los Angeles, USA)
  • Eric SIEMERS (Philadelphia, USA)
  • Sietske SIKKES (Amsterdam, NL)
  • Yong SHEN (Heife, China)
  • Jiong SHI (Las Vegas, USA)
  • Heather SNYDER (Chicago, USA)
  • Reisa SPERLING (Boston, USA)*
  • Yaakov STERN (New York, USA)
  • Duygu TOSUN (San Francisco, USA)
  • Jacques TOUCHON (Montpellier, France)*
  • Wiesje VAN DER FLIER (Amsterdam, The Netherlands)
  • Christopher H. VAN DYCK (New Haven, USA)
  • Bruno VELLAS (Toulouse, France)
  • Prashanthi VEMURI (San Francisco, USA)
  • Michael W. WEINER (San Francisco, USA)*
  • Donna M. WILCOCK (Indianapolis, USA)
  • Bengt WINBLAD (Stockholm, Sweden)
  • Jin-Tai YU (Shanghai, China)